Skip to content
NBDC Human Database

No datasets in the cart.

Go to the cart

Due to system maintenance, the application system, application review by the Data Access Committee will be unavailable during the following period.
Schedule: October 5th (Mon), 2026, 9:00 - October 7th (Wed), 2026, 15:00 (JST)
We apologize for any inconvenience this may cause and appreciate your understanding.

We are currently receiving a large number of applications for data submission, and the review process is taking longer than usual.We sincerely apologize for the delay and kindly ask for your understanding. When submitting an application, we would greatly appreciate it if you could allow sufficient time for the processing.

Following a change to our organizational structure effective April 1, 2026, this division has been renamed from the "Database Center for Life Science, Joint Support-Center for Data Science Research" to the "Database Division for Life Science (DBCLS), BioData Science Initiative (BSI), National Institute of Genetics (NIG)". Where the former name still appears in the guidelines, please read it as the new name.

Dataset ID

JGAD000432

Type of data
NGS (WGS)
NGS (scRNA-seq)
NGS (TCR-seq)
NGS (BCR-seq)
CyTOF
Access criteria
Controlled-access (Type I)
Total data volume
2.2 TB
File formats
  • FASTQ
  • TXT
Research
hum0290
Date published
2022-02-17
Date modified
2022-02-17
DDBJ Search
JGAD000432 (opens in a new tab)
JGA Study
JGAS000321 (opens in a new tab)

Unrestricted-access files linked to this dataset

Download the URL list
FileLabelSizeCopy URL
Fluidimg_MarkerList.xlsx30 proteins related to immune response10.1 KB
JPN-Maxpar-Direct-Immune-Profiling-System-flyer-FLDM-A4-2page.pdf1.0 MB
Maxpar-Direct-Immune-Profiling-System-flyer-FLDM-400246-Rev04.pdf1.9 MB

Analysis method

WGS

Materials and participants
2 healthy volunteers (2 samples)
  • Health status
    Healthy
  • Subject count
    2 (Individual)
Sample description
DNAs extracted from peripheral blood cells
  • Tissue
    Peripheral blood
  • Tumor / normal
    Normal
Sample provider
N/A
Experimental method
WGS
Target
N/A
Reagent kit
Ligation Sequencing Kit (SQK-LSK109)
TruSeq Nano DNA Library Prep Kit
Fragmentation
Illumina: Ultrasonic fragmentation (Covaris)
Nanopore: -
Platform
Illumina NovaSeq 6000
Oxford Nanopore Technologies PromethION
Read type
Mixed
Read length
Illumina: 300 bp
Data use policy
NBDC data sharing policy (JGAP000001)

scRNA-seq

Materials and participants
7 healthy volunteers (57 samples)
  • Health status
    Healthy
  • Subject count
    7 (Individual)
Sample description
RNAs extracted from peripheral blood cells
  • Tissue
    Peripheral blood
  • Tumor / normal
    Normal
Sample provider
N/A
Experimental method
scRNA-seq
Target
N/A
Reagent kit
Chromium Next GEM Single Cell V(D)J v1.1
Fragmentation
Enzymatic fragmentation
Platform
10x Genomics Chromium
Read type
Single-end
Read length
91 bp
Data use policy
NBDC data sharing policy (JGAP000001)

TCR-seq

Materials and participants
7 healthy volunteers (57 samples)
  • Health status
    Healthy
  • Subject count
    7 (Individual)
Sample description
RNAs extracted from peripheral blood cells
  • Tissue
    Peripheral blood
  • Tumor / normal
    Normal
Sample provider
N/A
Experimental method
TCR-seq
Target
N/A
Reagent kit
Chromium Next GEM Single Cell V(D)J v1.1
Fragmentation
Enzymatic fragmentation
Platform
10x Genomics Chromium
Read type
Single-end
Read length
91 bp
Data use policy
NBDC data sharing policy (JGAP000001)

BCR-seq

Materials and participants
7 healthy volunteers (35 samples)
  • Health status
    Healthy
  • Subject count
    7 (Individual)
Sample description
RNAs extracted from peripheral blood cells
  • Tissue
    Peripheral blood
  • Tumor / normal
    Normal
Sample provider
N/A
Experimental method
BCR-seq
Target
N/A
Reagent kit
Chromium Next GEM Single Cell V(D)J v1.1
Fragmentation
Enzymatic fragmentation
Platform
10x Genomics Chromium
Read type
Single-end
Read length
91 bp
Data use policy
NBDC data sharing policy (JGAP000001)

Mass cytometry (CyTOF)

Materials and participants
6 healthy volunteers (30 samples)
  • Health status
    Healthy
  • Subject count
    6 (Individual)
Sample description
peripheral blood cells
  • Tissue
    Peripheral blood
  • Tumor / normal
    Normal
Experimental variable
individual variation, timepoint post-vaccination, vaccination type (influenza, SARS-CoV-2)
Sample provider
N/A
Experimental method
CyTOF
Target
30 proteins related to immune response
Reagent kit
Maxpar Direct Immune Profiling Assay
Platform
Fluidigm Helios
Analysis method
Maxpar Pathsetter (Cat. #401018)
Phenotype data
Included
Data use policy
NBDC data sharing policy (JGAP000001)